Shots:

• The company plans to file for an interchangeable biosimilar of adalimumab in the US and is expected to launch Humira biosimilar Abrilada (adalimumab-afzb) in July 2023
• Additionally, the company also plans to launch Cyltezo, an adalimumab biosimilar in 2023 & has received interchangeable status from the US FDA
• The company has multiple oncology biosimilars and supportive oncology biosimilars & also has Retracrit (epoetin alfa), Nivestym (filgrastim), and Nyvepria (pegfilgrastim) that allows the patients to recover from blood-cell depletion following CT

/ article | Ref: The Wall Street Journal | Image: Pfizer